Literature DB >> 16115926

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.

Amanda Psyrri1, Ziwei Yu, Paul M Weinberger, Clarence Sasaki, Bruce Haffty, Robert Camp, David Rimm, Barbara Ann Burtness.   

Abstract

BACKGROUND: Several lines of evidence support the epidermal growth factor receptor (EGFR) as a molecular target for therapy in head and neck squamous cell carcinomas (HNSCC). Determination of tumor EGFR levels by conventional immunohistochemistry has not always predicted antitumor efficacy. Quantitative assays may provide more accurate assessment of the level of EGFR receptor in the tumor, which may thus provide more reliable prognostic and predictive information. We studied the prognostic value of quantitative assessment of EGFR in oropharyngeal squamous cell cancers treated with radiotherapy. EXPERIMENTAL
DESIGN: We studied EGFR protein expression on a tissue microarray composed of 95 oropharyngeal cancer cases using an in situ molecular-based method of quantitative assessment of protein expression (AQUA) and correlated those with clinical and pathologic data. Automated, quantitative analysis uses cytokeratin to define pixels as cancer (tumor mask) within the array spot and measures intensity of EGFR expression using a Cy5-conjugated antibody within the mask. A continuous index score is generated, which is directly proportional to the number of molecules per unit area, and cases were defined as high expressing if they were above the median expression level.
RESULTS: The mean follow-up time for survivors was 44.9 months, and for the entire cohort was 34.8 months. Patients with high tumor EGFR expression levels had a local recurrence rate of 58% compared with 17% for patients with low EGFR tumor expression (P < 0.01). Similarly, patients with high nuclear EGFR expression had a local recurrence rate of 54% compared with 21% for patients with low EGFR nuclear expression (P < 0.05). Additionally, patients with high tumor and nuclear EGFR levels had inferior disease-free survival compared with low expressors (19% versus 43% and 19% versus 45%, respectively. P < 0.05 for each). In multivariate analysis adjusting for well-characterized prognostic variables, high tumor and nuclear EGFR expression levels retained their prognostic significance.
CONCLUSION: The AQUA system provides a continuous measurement of EGFR on paraffin-embedded tissue and was able to reveal the association between EGFR expression and outcome expected from the biological role of EGFR. In the future, EGFR AQUA score may be useful in predicting response to EGFR-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115926     DOI: 10.1158/1078-0432.CCR-05-0420

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  110 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 2.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

3.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Authors:  K Kian Ang; Qiang Zhang; David I Rosenthal; Phuc Felix Nguyen-Tan; Eric J Sherman; Randal S Weber; James M Galvin; James A Bonner; Jonathan Harris; Adel K El-Naggar; Maura L Gillison; Richard C Jordan; Andre A Konski; Wade L Thorstad; Andy Trotti; Jonathan J Beitler; Adam S Garden; William J Spanos; Sue S Yom; Rita S Axelrod
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Mol Biol Cell       Date:  2007-01-10       Impact factor: 4.138

Review 5.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

Review 6.  Tissue microarrays in clinical oncology.

Authors:  David Voduc; Challayne Kenney; Torsten O Nielsen
Journal:  Semin Radiat Oncol       Date:  2008-04       Impact factor: 5.934

7.  Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells.

Authors:  Ye Yuan; Si Chen; Tatjana Paunesku; Sophie Charlotte Gleber; William C Liu; Caroline B Doty; Rachel Mak; Junjing Deng; Qiaoling Jin; Barry Lai; Keith Brister; Claus Flachenecker; Chris Jacobsen; Stefan Vogt; Gayle E Woloschak
Journal:  ACS Nano       Date:  2013-11-27       Impact factor: 15.881

8.  Nuclear EGFR is required for cisplatin resistance and DNA repair.

Authors:  Sheng-Chieh Hsu; Stephanie A Miller; Yan Wang; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2009-03-08       Impact factor: 4.060

9.  A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.

Authors:  Soner Altiok; Heather Mezzadra; Sanjay Jagannath; Nancy Tsottles; Michelle A Rudek; Nadia Abdallah; David Berman; Arlene Forastiere; Michael K Gibson
Journal:  Int J Oncol       Date:  2010-01       Impact factor: 5.650

Review 10.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.